Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenying Shan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|May 24, 2022
The development of small-molecule inhibitors targeting hexokinase 2Wenying Shan, Yan Zhou, Kin Yip Tam
Current Medicinal Chemistry|May 27, 2020
Convolutional Neural Network-based Virtual ScreeningWenying Shan, Xuanyi Li, Hequan Yao, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|April 18, 2025
Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutationWenying Shan, Shao-Lin Zhang, Yehuda G Assaraf, et al.
European Journal of Medicinal Chemistry|March 15, 2026
AI-driven identification of a selective dual function inhibitor blocking HK2 activity and HK2-VDAC1 interaction displaying enhanced anticancer efficacy under hypoxiaWenying Shan, Shao-Lin Zhang, Yehuda G Assaraf, et al.
Translational Oncology|January 22, 2026
NF-κB activation as a pro-survival signal from pharmacological inhibition of pyruvate dehydrogenase kinase 1 in non-small-cell lung carcinoma cell modelsQuan Liu, Maoxin Ran, Wenying Shan, et al.
ADMET & DMPK|December 23, 2024
Targeting hexokinase 2 to enhance anticancer efficacy of trichosanthin in HeLa and SCC25 cell modelsYan Zhou, Maoxin Ran, Wenying Shan, et al.
Frontiers in Chemistry|November 6, 2023
GcForest-based compound-protein interaction prediction model and its application in discovering small-molecule drugs targeting CD47Wenying Shan, Lvqi Chen, Hao Xu, et al.
Phytotherapy Research : PTR|August 25, 2023
Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axisYan Zhou, Shiqi Huang, Yizhen Guo, et al.
Chemico-Biological Interactions|April 2, 2023
Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer modelsYizhen Guo, Yan Zhou, Puhua Wu, et al.
Biochemical Pharmacology|June 26, 2025
Benserazide‑mediated targeting hexokinase 2 enhances the cytotoxicity of cisplatin in non-small cell lung cancer cell modelsKaifang Wang, Suya Wang, Wenying Shan, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|May 24, 2022
The development of small-molecule inhibitors targeting hexokinase 2Wenying Shan, Yan Zhou, Kin Yip Tam
Current Medicinal Chemistry|May 27, 2020
Convolutional Neural Network-based Virtual ScreeningWenying Shan, Xuanyi Li, Hequan Yao, et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease|April 18, 2025
Combined inhibition of hexokinase 2 and pyruvate dehydrogenase surmounts SHP2 inhibitor resistance in non-small cell lung cancer with hybrid metabolic state harboring KRAS Q61H mutationWenying Shan, Shao-Lin Zhang, Yehuda G Assaraf, et al.
European Journal of Medicinal Chemistry|March 15, 2026
AI-driven identification of a selective dual function inhibitor blocking HK2 activity and HK2-VDAC1 interaction displaying enhanced anticancer efficacy under hypoxiaWenying Shan, Shao-Lin Zhang, Yehuda G Assaraf, et al.
Translational Oncology|January 22, 2026
NF-κB activation as a pro-survival signal from pharmacological inhibition of pyruvate dehydrogenase kinase 1 in non-small-cell lung carcinoma cell modelsQuan Liu, Maoxin Ran, Wenying Shan, et al.
ADMET & DMPK|December 23, 2024
Targeting hexokinase 2 to enhance anticancer efficacy of trichosanthin in HeLa and SCC25 cell modelsYan Zhou, Maoxin Ran, Wenying Shan, et al.
Frontiers in Chemistry|November 6, 2023
GcForest-based compound-protein interaction prediction model and its application in discovering small-molecule drugs targeting CD47Wenying Shan, Lvqi Chen, Hao Xu, et al.
Phytotherapy Research : PTR|August 25, 2023
Epigallocatechin gallate circumvents drug-induced resistance in non-small-cell lung cancer by modulating glucose metabolism and AMPK/AKT/MAPK axisYan Zhou, Shiqi Huang, Yizhen Guo, et al.
Chemico-Biological Interactions|April 2, 2023
Dichloroacetophenone biphenylsulfone ethers as anticancer pyruvate dehydrogenase kinase inhibitors in non-small cell lung cancer modelsYizhen Guo, Yan Zhou, Puhua Wu, et al.
Biochemical Pharmacology|June 26, 2025
Benserazide‑mediated targeting hexokinase 2 enhances the cytotoxicity of cisplatin in non-small cell lung cancer cell modelsKaifang Wang, Suya Wang, Wenying Shan, et al.
Pageof 2